[PART I FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20FINANCIAL%20INFORMATION) This section provides unaudited financial statements and management's analysis of financial condition and operations [Item 1. Financial Statements (unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents Regeneron Pharmaceuticals' unaudited condensed consolidated financial statements for Q2 and H1 2025, including balance sheets, statements of operations, stockholders' equity, and cash flows, with accompanying notes [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section provides a snapshot of the company's financial position, detailing assets, liabilities, and equity as of June 30, 2025, and December 31, 2024 Condensed Consolidated Balance Sheet Highlights (in millions) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and marketable securities | $17,527.8 | $17,912.6 | | Accounts receivable, net | $5,610.0 | $6,211.9 | | Total current assets | $16,859.5 | $18,660.9 | | Total assets | $38,219.2 | $37,759.4 | | **Liabilities & Equity** | | | | Total current liabilities | $3,667.0 | $3,944.3 | | Long-term debt | $1,985.1 | $1,984.4 | | Total liabilities | $8,280.3 | $8,405.8 | | Total stockholders' equity | $29,938.9 | $29,353.6 | [Condensed Consolidated Statements of Operations and Comprehensive Income](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Income) This section details the company's financial performance, including revenues, expenses, and net income for the three and six-month periods ended June 30, 2025 and 2024 Q2 2025 Statement of Operations Highlights (in millions, except per share data) | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenues | $3,675.6 | $3,547.1 | +3.6% | | Net Product Sales | $1,631.0 | $1,918.6 | -15.0% | | Collaboration Revenue | $1,860.7 | $1,524.0 | +22.1% | | R&D Expenses | $1,421.7 | $1,200.0 | +18.5% | | Income from Operations | $1,079.5 | $1,069.6 | +0.9% | | Net Income | $1,391.6 | $1,432.3 | -2.8% | | Diluted EPS | $12.81 | $12.41 | +3.2% | H1 2025 Statement of Operations Highlights (in millions, except per share data) | Metric | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenues | $6,704.3 | $6,692.1 | +0.2% | | Net Product Sales | $3,046.6 | $3,679.9 | -17.2% | | Collaboration Revenue | $3,391.9 | $2,790.8 | +21.5% | | R&D Expenses | $2,749.1 | $2,448.4 | +12.3% | | Income from Operations | $1,671.2 | $1,821.0 | -8.2% | | Net Income | $2,200.3 | $2,154.3 | +2.1% | | Diluted EPS | $20.02 | $18.68 | +7.2% | [Condensed Consolidated Statements of Stockholders' Equity](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders'%20Equity) This section outlines changes in stockholders' equity, reflecting net income, share repurchases, and dividends for the period - Total stockholders' equity increased from **$29.35 billion** at year-end 2024 to **$29.94 billion** as of June 30, 2025, primarily driven by net income of **$2.20 billion**[13](index=13&type=chunk)[12](index=12&type=chunk) - During the first six months of 2025, the company repurchased **3.4 million shares** of common stock for a total cost of **$2.12 billion**[13](index=13&type=chunk)[45](index=45&type=chunk) - The company declared and paid dividends totaling **$192.0 million** in the first six months of 2025[13](index=13&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section summarizes cash inflows and outflows from operating, investing, and financing activities for the six-month periods ended June 30, 2025 and 2024 Cash Flow Summary for Six Months Ended June 30 (in millions) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $2,189.5 | $1,866.5 | | Net cash used in investing activities | ($446.5) | ($2,244.3) | | Net cash used in financing activities | ($2,217.4) | ($431.0) | | **Net decrease in cash** | **($473.4)** | **($809.6)** | - The significant decrease in cash used in investing activities in H1 2025 compared to H1 2024 was mainly due to lower net purchases of marketable securities[16](index=16&type=chunk) - The increase in cash used in financing activities in H1 2025 was driven by higher common stock repurchases (**$2.1 billion** vs. **$895.2 million** in H1 2024) and the payment of dividends (**$186.4 million**)[16](index=16&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and breakdowns of significant accounting policies, product sales, collaboration revenues, and legal proceedings Net Product Sales for Three Months Ended June 30 (in millions) | Product | 2025 | 2024 | | :--- | :--- | :--- | | EYLEA HD (U.S.) | $393.2 | $304.2 | | EYLEA (U.S.) | $754.3 | $1,230.5 | | **Total EYLEA & EYLEA HD (U.S.)** | **$1,147.5** | **$1,534.7** | | Libtayo (Global) | $376.5 | $297.4 | - Regeneron's share of profits from the significant collaboration with Sanofi for Dupixent, Kevzara, and itepekimab was **$1.28 billion** in Q2 2025, up from **$988.3 million** in Q2 2024[21](index=21&type=chunk)[23](index=23&type=chunk) - The collaboration with Bayer for EYLEA outside the U.S. generated **$383.4 million** in profit share for Regeneron in Q2 2025, compared to **$353.0 million** in Q2 2024[24](index=24&type=chunk)[25](index=25&type=chunk) - The company is involved in numerous legal proceedings, primarily related to patent litigation for its key product EYLEA against several companies developing biosimilars, including Mylan, Celltrion, Samsung Bioepis, and Amgen[53](index=53&type=chunk)[54](index=54&type=chunk)[55](index=55&type=chunk) - The company is also involved in matters with the Department of Justice concerning allegations of violations of the federal Anti-Kickback Statute and False Claims Act related to EYLEA[75](index=75&type=chunk)[77](index=77&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's Q2 and H1 2025 financial performance, highlighting strong collaboration revenue growth offsetting declining U.S. EYLEA sales, alongside updates on product performance, clinical pipeline, and liquidity [Overview and Products](index=28&type=section&id=MD%26A%20-%20Overview%20and%20Products) This section provides an overview of Regeneron's business model and presents global net product sales for its key discovered products - Regeneron is a fully integrated biotechnology company focused on inventing, developing, manufacturing, and commercializing medicines for serious diseases across multiple therapeutic areas[91](index=91&type=chunk) Global Net Product Sales of Regeneron-Discovered Products (in millions) | Product | Q2 2025 | Q2 2024 | % Change | | :--- | :--- | :--- | :--- | | Total EYLEA HD and EYLEA | $2,125.2 | $2,442.5 | (13%) | | Dupixent | $4,344.6 | $3,556.4 | 22% | | Libtayo | $376.5 | $297.4 | 27% | | Praluent | $222.0 | $191.9 | 16% | [Clinical Development](index=32&type=section&id=MD%26A%20-%20Clinical%20Development) This section details regulatory updates, clinical trial results, and upcoming milestones for the company's pipeline products - Regulatory approvals for pending EYLEA HD applications are expected to be delayed due to FDA inspection observations at a third-party filler, Catalent[116](index=116&type=chunk) - The FDA issued a Complete Response Letter (CRL) for the BLA for Ordspono (odronextamab) in relapsed/refractory follicular lymphoma, also impacted by the Catalent site inspection[119](index=119&type=chunk) - A Phase 3 trial (AERIFY-1) for Itepekimab in COPD met its primary endpoint, but a second trial (AERIFY-2) did not, with the company discussing next steps with regulators[117](index=117&type=chunk) - Key upcoming milestones include an FDA decision on the sBLA for Libtayo in adjuvant CSCC in **October 2025** and results from a Phase 3 study of Fianlimab in first-line metastatic melanoma in **Q4 2025/Q1 2026**[108](index=108&type=chunk)[109](index=109&type=chunk) [Results of Operations](index=42&type=section&id=MD%26A%20-%20Results%20of%20Operations) This section analyzes the drivers behind changes in revenue, research and development expenses, selling, general and administrative expenses, and the effective tax rate - U.S. net product sales of EYLEA decreased significantly in Q2 and H1 2025 due to competitive pressures, loss of market share to compounded bevacizumab, and patient transition to EYLEA HD[136](index=136&type=chunk)[137](index=137&type=chunk) - Sanofi collaboration revenue increased by **$298.0 million** in Q2 2025, driven by higher profits from Dupixent sales[134](index=134&type=chunk)[139](index=139&type=chunk) - R&D expenses increased by **$221.7 million** in Q2 2025, primarily due to higher clinical manufacturing costs and increased spending on various clinical programs like Lynozyfic and Trevogrumab[142](index=142&type=chunk)[145](index=145&type=chunk) - SG&A expenses decreased by **$124.6 million** in Q2 2025, mainly due to lower charitable contributions to an independent patient assistance organization[142](index=142&type=chunk)[148](index=148&type=chunk) - The effective tax rate for Q2 2025 was **8.4%**, down from **12.0%** in Q2 2024, partly due to the release of liabilities for uncertain tax positions following an IRS audit settlement[152](index=152&type=chunk) [Liquidity and Capital Resources](index=47&type=section&id=MD%26A%20-%20Liquidity%20and%20Capital%20Resources) This section assesses the company's financial position, including cash, marketable securities, working capital, and capital allocation plans Financial Position (in millions) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $1,995.8 | $2,488.2 | | Marketable securities | $15,532.0 | $15,424.4 | | Working capital | $13,192.5 | $14,716.6 | - The company expects to incur capital expenditures of **$880 million to $950 million** for the full year 2025[157](index=157&type=chunk) - As of June 30, 2025, **$2.814 billion** remained available for share repurchases under the authorized programs[159](index=159&type=chunk) - The company initiated and paid quarterly cash dividends of **$0.88 per share** in Q1 and Q2 2025[160](index=160&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=48&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that there have been no material changes to its market risks or its management of such risks as of June 30, 2025, compared to what was disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - There have been no material changes to the company's market risks or its management of such risks as of June 30, 2025[164](index=164&type=chunk) [Item 4. Controls and Procedures](index=49&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2025, with no material changes in internal control over financial reporting during the quarter - The principal executive officer and principal financial officer concluded that the company's disclosure controls and procedures were effective as of the end of the period covered by the report[165](index=165&type=chunk) - No changes in internal control over financial reporting occurred during the quarter ended June 30, 2025, that have materially affected, or are reasonably likely to materially affect, internal controls[166](index=166&type=chunk) [PART II OTHER INFORMATION](index=49&type=section&id=PART%20II%20OTHER%20INFORMATION) This section covers other important disclosures, including legal proceedings, risk factors, equity security sales, and exhibits [Item 1. Legal Proceedings](index=49&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates detailed legal proceedings from Note 12, primarily concerning EYLEA patent litigation against biosimilar developers and Department of Justice investigations - Information regarding legal proceedings is incorporated by reference from Note 12 to the Condensed Consolidated Financial Statements[167](index=167&type=chunk) [Item 1A. Risk Factors](index=49&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks, including dependence on key products, intense competition, pricing pressures, development uncertainties, intellectual property litigation, and reliance on third-party collaborators - The company is substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent, with U.S. EYLEA sales declining due to competition and patient transition, and future sales likely impacted by biosimilar competition[179](index=179&type=chunk)[180](index=180&type=chunk) - Sales are dependent on coverage and reimbursement from third-party payors, and the Inflation Reduction Act (IRA) and other drug price control measures pose a significant risk to future profitability[187](index=187&type=chunk)[197](index=197&type=chunk)[199](index=199&type=chunk) - Drug development is costly and uncertain, with serious side effects or efficacy failures potentially leading to program delays or discontinuation, and regulatory approval is not guaranteed, as evidenced by recent CRLs due to third-party manufacturing issues[218](index=218&type=chunk)[241](index=241&type=chunk)[228](index=228&type=chunk) - The company faces significant intellectual property risks, including ongoing patent litigation for EYLEA and the potential for biosimilar competition to erode market exclusivity[252](index=252&type=chunk)[258](index=258&type=chunk)[264](index=264&type=chunk) - The company relies on limited internal and contracted manufacturing capacity, where failures at its own facilities or those of third-party suppliers could disrupt product supply[270](index=270&type=chunk)[275](index=275&type=chunk) - The company is subject to government investigations and legal challenges under healthcare laws like the Anti-Kickback Statute and False Claims Act, which could result in significant penalties[283](index=283&type=chunk)[287](index=287&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=87&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q2 2025, Regeneron repurchased approximately 1.93 million shares, with $2.81 billion remaining available under authorized share repurchase programs as of June 30, 2025 Issuer Purchases of Equity Securities (Q2 2025) | Period | Total Shares Purchased | Average Price Paid per Share | Shares Purchased as Part of Program | | :--- | :--- | :--- | :--- | | April 2025 | 615,505 | $577.66 | 609,388 | | May 2025 | 552,495 | $574.98 | 552,495 | | June 2025 | 767,705 | $510.97 | 763,732 | | **Total** | **1,935,705** | | **1,925,615** | - As of the end of June 2025, approximately **$2.814 billion** remained available for purchase under the company's share repurchase programs[351](index=351&type=chunk) [Item 5. Other Information](index=87&type=section&id=Item%205.%20Other%20Information) This section discloses that during the second quarter of 2025, Director Bonnie L. Bassler, Ph.D., adopted a Rule 10b5-1 trading plan for the potential sale of 5,121 securities, scheduled to end on May 1, 2026 - On May 2, 2025, Director Bonnie L. Bassler, Ph.D., adopted a Rule 10b5-1 trading plan for the sale of **5,121 securities**[352](index=352&type=chunk)[353](index=353&type=chunk) [Item 6. Exhibits](index=88&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including the Restated Certificate of Incorporation, an amendment to the collaboration agreement with Sanofi, officer certifications, and Interactive Data Files (Inline XBRL) - Exhibits filed include officer certifications (31.1, 31.2, 32), an amendment to the Sanofi collaboration agreement (10.1), and Inline XBRL data files (101, 104)[354](index=354&type=chunk)

Exhibit 99.1 Press Release Regeneron Reports Second Quarter 2025 Financial and Operating Results Tarrytown, New York (August 1, 2025) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2025 and provided a business update. "Regeneron had a strong quarter, marked by significant growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo along with multiple regulatory approvals," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, Pre ...

Core Insights - Regeneron Pharmaceuticals reported strong financial results for Q2 2025, with notable growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo, alongside multiple regulatory approvals [2][3][5] Financial Highlights - Total revenues for Q2 2025 reached $3.68 billion, a 4% increase from $3.55 billion in Q2 2024 [3][12] - GAAP net income was $1.39 billion, down 3% from $1.43 billion in the same quarter last year, while non-GAAP net income increased by 5% to $1.42 billion [3][12] - Non-GAAP net income per share rose 12% to $12.89, compared to $11.56 in Q2 2024 [3][12] Business Highlights - Dupixent global net sales increased by 22% to $4.34 billion, while EYLEA HD U.S. net sales grew by 29% to $393 million [5][12] - The FDA approved Lynozyfic for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria [5][10] - The company has approximately 45 product candidates in clinical development, with significant progress in its oncology portfolio [4][5] Regulatory and Pipeline Updates - The FDA accepted for priority review Libtayo's supplemental Biologics License Application for adjuvant cutaneous squamous cell carcinoma, with a target action date in October 2025 [10][11] - The company reported interim results from the Phase 2 COURAGE trial, showing promising data for obesity treatment [10][11] Capital Allocation - Regeneron returned over $2.3 billion to shareholders through share repurchases and dividends, while committing over $7 billion to U.S. manufacturing investments and business development since the start of 2025 [3][23] - A cash dividend of $0.88 per share was declared, payable on September 3, 2025 [24]

Regeneron Pharmaceuticals, Inc. REGN will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1. Analysts expect the Tarrytown, New York -based company to report quarterly earnings at $8.43 per share, down from $11.56 per share in the year-ago period. Regeneron Pharmaceuticals projects to report quarterly revenue at $3.28 billion, compared to $3.55 billion a year earlier, according to data from Benzinga Pro. On July 2, the U.S. Food and Drug Administration (FDA) granted ...

Financial Data and Key Metrics Changes - Net sales increased by 10.1% at constant exchange rates in Q2, primarily driven by immunology, biopharma launches, and Befortus [16][26] - Business EPS was €1.59, up 8.3%, reflecting strong sales performance and improved gross margin [18][26] - Gross margin improved by 1.5 percentage points, largely due to an improved product mix and efficiencies [16][18] Business Line Data and Key Metrics Changes - New launches generated close to €1,000,000,000 in sales, representing 10% of total sales [7][10] - Dupixent sales reached €3,800,000,000, up 21% in Q2, driven by strong demand across geographies [10][11] - Vaccine business sales increased by 10.3%, benefiting from the late flu season in the Northern Hemisphere [11][12] Market Data and Key Metrics Changes - Dupixent sales in the U.S. reached €2,800,000,000, up 22.7%, leading in new to brand prescriptions [10] - Outside the U.S., sales exceeded $1,000,000,000, driven by volume growth in key markets [10] - Anticipated sales split for flu vaccines is about 75% in Q3 and 25% in Q4, with total sales expected to decrease by a mid-teens percentage due to competitive pressures [25][26] Company Strategy and Development Direction - The company refined its 2025 sales guidance to high single-digit percentage growth at constant exchange rates, reflecting confidence in growth drivers [6][26] - The completion of the Blueprint Medicines acquisition strengthens the company's position in rare immunology diseases [13][14] - The company is committed to sustainability, aiming for all new medicines and vaccines to incorporate eco-design principles by 2025 [15][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the full-year business outlook, supported by strong performance from growth drivers [6][26] - The company is navigating uncertainties from potential U.S. tariffs and EU exports, with updates to be provided as more information becomes available [27][28] - Management remains optimistic about the pipeline and the potential for new product launches to drive future growth [41][45] Other Important Information - R&D expenses increased by 17.7% due to a lower base of comparison last year, with underlying R&D expenses up around 7% [17][18] - The company is executing a €5,000,000,000 share buyback program in 2025, with over 80% already completed [21][22] Q&A Session Summary Question: R&D transformation and pipeline progress - Management acknowledged the progress in R&D but noted that the share price is lagging, awaiting further pipeline developments [41][42] - Confidence remains in the Phase III trials and the potential for achieving €10 billion in sales by 2030 [42][43] Question: Development spend and margin outlook - R&D expenses are expected to be slightly up in H2, with SG&A increasing at half the rate of sales growth [50][52] - Management anticipates BOI margin growth alongside absolute growth in the coming years [54][56] Question: Dupixent performance in China - Dupixent has seen over 30% volume growth in China, despite pricing pressures [58][59] Question: Expectations for amlitilumab and tariffs - The company has not factored potential tariff impacts into its 2025 guidance, expecting limited effects due to existing inventory [63][64] - Amlitilumab is expected to provide comparable efficacy to existing treatments with a longer dosing interval [66][67]

Financial Data and Key Metrics Changes - Net sales increased by 10.1% at constant exchange rates in Q2 2025, primarily driven by immunology, biopharma launches, and Befortus [15][25] - Business EPS was €1.59, up 8.3%, reflecting strong sales performance and improved gross margin [15][25] - Gross margin improved by 1.5 percentage points due to an improved product mix and efficiencies [15] Business Line Data and Key Metrics Changes - New launches generated close to €1,000,000,000 in sales, representing 10% of total sales [6][7] - Dupixent sales reached €3,800,000,000, up 21% in Q2, driven by strong demand across geographies [7][8] - Vaccine business sales increased by 10.3%, benefiting from the late flu season in the Northern Hemisphere [9][10] Market Data and Key Metrics Changes - Dupixent sales in the U.S. reached €2,800,000,000, up 22.7%, leading in both new to brand prescriptions and total prescriptions [8] - Outside the U.S., sales exceeded $1,000,000,000, driven by volume growth in key markets [8] - Anticipated sales split for flu vaccines is about 75% in Q3 and 25% in Q4, with total sales expected to decrease by a mid-teens percentage due to competitive pressures [24][25] Company Strategy and Development Direction - The company refined its 2025 sales guidance to high single-digit percentage growth at constant exchange rates, reflecting confidence in growth drivers [5][25] - The completion of the Blueprint Medicines acquisition strengthens the company's position in rare immunology diseases and enhances its pipeline [12][18] - The company is committed to sustainability, aiming for all new medicines and vaccines to incorporate eco-design principles by 2025 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the full-year business outlook, supported by strong performance from growth drivers [5][25] - The company is navigating uncertainties from potential U.S. tariffs and EU exports, with updates to be provided as more information becomes available [26] - Management highlighted the importance of maintaining a strong market share despite competitive pricing pressures in the flu vaccine market [24][25] Other Important Information - The company is executing a €5,000,000,000 share buyback program in 2025, with over 80% already completed [20] - The anticipated negative year-on-year BOI impact from Regeneron reimbursement is approximately €300,000,000 in 2026 and €800,000,000 in 2027 [22] Q&A Session Summary Question: R&D transformation and pipeline progress - Management acknowledged the progress in R&D but noted that the share price is lagging, indicating a need for pipeline advancements [42][43] - Confidence remains in achieving the targeted increase in Phase III trials and the potential for significant sales by 2030 [43][46] Question: Development spend and pricing pressures - R&D expenses are expected to be slightly up in H2, with SG&A increasing at half the rate of sales growth [51][55] - Management confirmed that pricing pressures in the flu market are being addressed, with expectations for continued market share despite competitive dynamics [72][75] Question: Dupixent growth in China - Dupixent has seen over 30% volume growth in China, with management optimistic about future growth despite pricing pressures [60][62] Question: Expectations for amlitelemab and tariffs - Management emphasized the importance of efficacy and treatment duration for amlitelemab in the atopic dermatitis market [68][69] - No significant impact from tariffs is expected for 2025 due to existing inventory [66][67]

Core Insights - Sensei Biotherapeutics, Inc. announced the presentation of clinical data from the Phase 1/2 trial of solnerstotug, both alone and in combination with Libtayo, at the ESMO Congress 2025 in Berlin [1] Company Overview - Sensei Biotherapeutics is a clinical stage biotechnology company focused on developing next-generation therapeutics for cancer patients [2] - The company utilizes its TMAb™ platform to create conditionally active therapeutics that target immunosuppressive signals in the tumor microenvironment [2] - Solnerstotug is the lead product candidate, designed to block the VISTA checkpoint selectively in low pH tumor environments, enhancing T cell activation [2]

Core Viewpoint - Analysts forecast Regeneron (REGN) will report quarterly earnings of $8.03 per share, reflecting a year-over-year decline of 30.5%, with anticipated revenues of $3.34 billion, a decrease of 5.7% compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised downward by 6.5% over the past 30 days, indicating a collective reassessment by analysts [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3]. Revenue Forecasts - Analysts predict 'Revenues- Other Revenue' at $125.38 million, a year-over-year increase of 20% [5]. - 'Revenues- Net product sales' are expected to reach $1.46 billion, reflecting a decline of 23.9% year-over-year [5]. - 'Total Bayer collaboration revenue' is projected at $388.54 million, indicating a year-over-year increase of 3.6% [5]. - The consensus estimate for 'Revenues- Collaboration' stands at $1.73 billion, a year-over-year increase of 13.7% [6]. - 'Revenues- Eylea (Aflibercept)- US' are expected to be $1.03 billion, down 33% from the prior year [6]. - 'Revenues- Praluent (alirocumab)- US' are forecasted at $54.57 million, a decrease of 2.7% year-over-year [6]. Product-Specific Revenue Insights - 'Revenues- Libtayo- US' are estimated to reach $234.04 million, reflecting a year-over-year increase of 28.3% [7]. - 'Revenues- Evkeeza- US' are expected at $36.84 million, indicating an 18.8% year-over-year increase [7]. - 'Revenues- Dupixent (dupilumab)- ROW' are projected at $1.16 billion, a year-over-year increase of 22.7% [8]. - 'Revenues- Dupixent (dupilumab)- US' are expected to reach $3.05 billion, reflecting a year-over-year increase of 16.7% [8]. - 'Revenues- Kevzara (sarilumab)- ROW' are estimated at $47.83 million, indicating a year-over-year increase of 7.2% [9]. Market Performance - Over the past month, shares of Regeneron have returned +6.4%, outperforming the Zacks S&P 500 composite's +3.6% change [9].

Company Overview - Regeneron is expected to report a year-over-year decline in earnings, with a projected EPS of $8.15, reflecting a decrease of 29.5% compared to the previous year [3] - Revenues are anticipated to be $3.34 billion, down 5.7% from the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised down by 6.49% over the last 30 days, indicating a reassessment by analysts [4] - The Most Accurate Estimate for Regeneron is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +7.62% [12] Earnings Surprise Potential - Regeneron has a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] - Historically, Regeneron has beaten consensus EPS estimates three out of the last four quarters [14] Market Expectations - The stock price may increase if the actual earnings exceed expectations in the upcoming report, scheduled for August 1 [2] - Conversely, if the earnings miss expectations, the stock may decline [2] Industry Context - Alnylam Pharmaceuticals, another player in the biomedical sector, is expected to report a loss of $0.03 per share, indicating a significant year-over-year decline of 105.4% [18] - Alnylam's revenues are projected to be $671.11 million, up 1.7% from the previous year, with a substantial positive Earnings ESP of +831.25% [19][20]

Core Insights - Investors are focusing on profits from asthma drug Dupixent and sales of Eylea HD as Regeneron Pharmaceuticals prepares to report Q2 2025 results on August 1, 2025, with revenue estimates at $3.34 billion and earnings at $8.15 per share [1][9] Financial Performance - Regeneron has a history of earnings surprises, beating estimates in three of the last four quarters with an average surprise of 4.20%, although it missed by 2.49% in the last quarter [2] - The earnings ESP for Regeneron is +7.62%, indicating a potential earnings beat, supported by a Zacks Rank of 3 (Hold) [4][3] Product Sales - Eylea, a significant revenue source, has faced sales pressure due to competition from Vabysmo, with estimates for Q2 sales in the U.S. at $1 billion [5][6][7] - The introduction of Eylea HD has seen strong initial uptake, which may help offset the decline in legacy Eylea sales [7] - Dupixent is expected to drive growth, with sales estimates at $4.2 billion, bolstered by strong prescription trends across various indications [10][8] Pipeline and Regulatory Updates - Regeneron is diversifying its revenue base to reduce dependence on Eylea, with ongoing efforts to expand its oncology franchise, including Libtayo, which has sales estimates of $322 million [11][12] - Recent approvals for Dupixent and linvoseltamab-gcpt (Lynozyfic) enhance Regeneron's pipeline, with Lynozyfic receiving accelerated approval for treating relapsed or refractory multiple myeloma [16][17] Operating Expenses and Share Repurchase - Operating expenses are expected to rise due to pipeline advancements and commercialization efforts for Eylea HD [14] - A new share repurchase program of up to $3 billion was authorized, with $3.874 billion remaining available as of March 31, 2025 [15] Stock Performance - Regeneron's shares have declined by 20.5% year-to-date, contrasting with a 3.3% decline in the industry [18]